Fig. 2From: Results on patient-reported outcomes are underreported in summaries of product characteristics for new drugsReporting rate of PROs in SmPCs: a by outcome category, b by outcome/disease category. *Proportion of RCTs with evaluable PRO data reported in the SmPCs. HRQoL health-related quality of life, N number of RCTs with evaluable PRO data included in dossier assessments, PRO patient-reported outcome, SmPC summary of product characteristicsBack to article page